FDA Approves Novartis’ Lutathera For Pediatric Gastroenteropancreatic Neuroendocrine Tumors
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Novartis (NVS) said that the U.S. Food and Drug Administration approved Lutathera for the treatment of pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuro
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1824226142-5daaa8e03e6e497a90c9658c943d8693.jpg "How Serial Entrepreneurs Are Reshaping Wealth Creation")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2058309470-c33b092093a4445098775c2b8bd538fe.jpg "Best Dividend Stocks for November 2024")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1451277892-5d6677cb7ffe42999ba03f993d1a1ba8.jpg "Are My Social Security Disability Benefits Taxable?")